Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease
Internal Medicine Journal · 2026-07 · 56 (7) · 1218-1239
DOI: 10.1111/imj.70460 ↗Kurz gefasst
Leitlinie in der Zeitschrift Internal Medicine Journal, online erschienen am 30.05.2026. Verfasst von Dipti Talaulikar und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Psychology, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory, Australia. Hauptthemen laut MEDLINE: Castleman Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Idiopathic multicentric Castleman disease (iMCD) is a rare condition. The pathogenesis is incompletely understood; however, interleukin‐6 (IL‐6) is a major mediator. The clinical presentation is heterogeneous, from mild constitutional symptoms to severe multi‐organ failure. The diagnosis is challenging, as it incorporates clinicopathologic criteria and requires careful evaluation to exclude various systemic disorders. Targeting IL‐6 activity forms the cornerstone of modern therapy for iMCD, with siltuximab recommended as first‐line therapy. Rituximab‐based regimens are recommended for second‐line therapy. However, many patients do not achieve adequate responses with limited evidence to guide further therapy. In the context of these substantial challenges, herein we provide a multidisciplinary Australasian clinical practice guideline to characterise clinical and pathological features, summarise treatment pathways and discuss clinical outcomes of the condition. The objective is to develop a multidisciplinary clinical practice guideline in the diagnosis and management of iMCD in Australia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine and Psychology, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory, Australia.
- Department of Haematology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
- Department of Haematology, Liverpool Hospital, Sydney, New South Wales, Australia.
- Department of Haematology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
- School of Clinical Medicine, UNSW Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
- Department of Rheumatology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
ORCID-Profile: Dipti Talaulikar, Adam Bryant, Simon J Harrison, H Miles Prince, Alberta Hoi
Zitieren
APA
Talaulikar, D., Ng, J. Y., Bryant, A., Bosco, A., Caterson, H. C., Giri, P., Hissaria, P., Harrison, S. J., Lade, S., Leslie, C., Perram, J., Prince, H. M., Radeski, D., Rischmueller, M., Wallington-Gates, C., Weber, N., & Hoi, A. (2026). Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease. Internal Medicine Journal, 56(7), 1218-1239. https://doi.org/10.1111/imj.70460
Vancouver
Talaulikar D, Ng JY, Bryant A, Bosco A, Caterson HC, Giri P, et al. Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease. Internal Medicine Journal. 2026;56(7):1218-1239. doi:10.1111/imj.70460
BibTeX
@article{Talaulikar2026,
author = {Talaulikar, Dipti and Ng, Jun Yen and Bryant, Adam and Bosco, Annmarie and Caterson, Hugh C and Giri, Pratyush and Hissaria, Pravin and Harrison, Simon J and Lade, Stephen and Leslie, Connull and Perram, Jacinta and Prince, H Miles and Radeski, Dejan and Rischmueller, Maureen and Wallington-Gates, Craig and Weber, Nicholas and Hoi, Alberta},
title = {Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease},
journal = {Internal Medicine Journal},
year = {2026},
volume = {56},
number = {7},
pages = {1218--1239},
doi = {10.1111/imj.70460}
}
EUVIMED